Gene amplification and associated loss of 5′ regulatory sequences of CoAA in human cancers

Oncogene

Volumn 26, Issue 6, 2007, Pages 822-835

  Sui, Y ^a   Yang, Z ^a   Xiong, S ^a   Zhang, L ^a   Blanchard, K L ^b   Peiper, S C ^a   Dynan, W S ^a   Tuan, D ^a   Ko, L ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

CoAA oncogene; Gene amplification; Transcriptional coactivator

Indexed keywords

COACTIVATOR ACTIVATOR PROTEIN; MESSENGER RNA; ONCOPROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; AMPLICON; ARTICLE; BIOASSAY; CANCER GENETICS; CARCINOGENESIS; CHROMOSOME 11Q; CONTROLLED STUDY; DNA FLANKING REGION; DOT HYBRIDIZATION; GENE AMPLIFICATION; GENE LOCUS; GENE LOSS; GENE MAPPING; GENE OVEREXPRESSION; GENE SEQUENCE; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; LYMPHOMA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN SYNTHESIS INHIBITION; RNA ANALYSIS; SQUAMOUS CELL CARCINOMA; UPREGULATION;

ANIMALS; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOMES, HUMAN, PAIR 11; CYCLINS; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HAPLORHINI; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENE PROTEINS; PROMOTER REGIONS (GENETICS); REGULATORY SEQUENCES, NUCLEIC ACID; RNA, MESSENGER; UP-REGULATION;

EID: 33846946819     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1209847     Document Type: Article

References (40)

1. Antonson P, Schuster GU, Wang L, Rozell B, Holter E, Flodby P et al. (2003). Inactivation of the nuclear receptor coactivator RAP250 in mice results in placental vascular dysfunction. Mol Cell Biol 23: 1260-1268.
2. Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY et al. (1997). AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277: 965-968.
3. Aranda A, Pascual A. (2001). Nuclear hormone receptors and gene expression. Physiol Rev 81: 1269-1304.
4. Auboeuf D, Dowhan DH, Dutertre M, Martin N, Berget SM, O'Malley BW. (2005). A subset of nuclear receptor coregulators act as coupling proteins during synthesis and maturation of RNA transcripts. Mol Cell Biol 25: 5307-5316.
5. Auboeuf D, Dowhan DH, Li X, Larkin K, Ko L, Berget SM et al. (2004). CoAA, a nuclear receptor coactivator protein at the interface of transcriptional coactivation and RNA splicing. Mol Cell Biol 24: 442-453.
6. Auboeuf D, Honig A, Berget SM, O'Malley BW. (2002). Coordinate regulation of transcription and splicing by steroid receptor coregulators. Science 298: 416-419.
7. Brett D, Whitehouse S, Antonson P, Shipley J, Cooper C, Goodwin G. (1997). The SYT protein involved in the t(X;18) synovial sarcoma translocation is a transcriptional activator localised in nuclear bodies. Hum Mol Genet 6: 1559-1564.
8. Buttel I, Fechter A, Schwab M. (2004). Common fragile sites and cancer: targeted cloning by insertional mutagenesis. Ann NY Acad Sci 1028: 14-27.
9. Bystritskiy AA, Razin SV. (2004). Breakpoint clusters: reason or consequence? Crit Rev Eukaryot Gene Expr 14: 65-77.
10. Caiafa P, Zampieri M. (2005). DNA methylation and chromatin structure: the puzzling CpG islands. J Cell Biochem 94: 257-265.
11. Clark J, Rocques PJ, Crew AJ, Gill S, Shipley J, Chan AM et al. (1994). Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma. Nat Genet 7: 502-508.
12. Coquelle A, Pipiras E, Toledo F, Buttin G, Debatisse M. (1997). Expression of fragile sites triggers intrachromosomal mammalian gene amplification and sets boundaries to early amplicons. Cell 89: 215-225.
13. Das PM, Singal R. (2004). DNA methylation and cancer. J Clin Oncol 22: 4632-4642.
14. Fox AH, Lam YW, Leung AK, Lyon CE, Andersen J, Mann M et al. (2002). Paraspeckles: a novel nuclear domain. Curr Biol 12: 13-25.
15. Gibbons R, Dugaiczyk A. (2005). Phylogenetic roots of Alu-mediated rearrangements leading to cancer. Genome 48: 160-167.
16. Grandinetti KB, Spengler BA, Biedler JL, Ross RA. (2006). Loss of one HuD allele on chromosome #1p selects for amplification of the N-myc proto-oncogene in human neuroblastoma cells. Oncogene 25: 706-712.
17. Greaves MF, Wiemels J. (2003). Origins of chromosome translocations in childhood leukaemia. Nat Rev Cancer 3: 639-649.
18. Guan XY, Xu J, Anzick SL, Zhang H, Trent JM, Meltzer PS. (1996). Hybrid selection of transcribed sequences from microdissected DNA: isolation of genes within amplified region at 20q11-q13.2 in breast cancer. Cancer Res 56: 3446-3450.
19. Iwasaki T, Chin WW, Ko L. (2001). Identification and characterization of RRM-containing coactivator activator (CoAA) as TRBP-interacting protein, and its splice variant as a coactivator modulator (CoAM). J Biol Chem 276: 33375-33383.
20. Jasinska A, Krzyzosiak WJ. (2004). Repetitive sequences that shape the human transcriptome. FEBS Lett 567: 136-141.
21. Kalnina Z, Zayakin P, Silina K, Line A. (2005). Alterations of pre-mRNA splicing in cancer. Genes Chromosomes Cancer 42: 342-357.
22. Kim CF, Jackson EL, Woolfenden AE, Lawrence S, Babar I, Vogel S et al. (2005). Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 121: 823-835.
23. Kim J, Pelletier J. (1999). Molecular genetics of chromosome translocations involving EWS and related family members. Physiol Genom. 1: 127-138.
24. Ko L, Cardona GR, Chin WW. (2000). Thyroid hormone receptor-binding protein, an LXXLL motif-containing protein, functions as a general coactivator. Proc Natl Acad Sci USA 97: 6212-6217.
25. Koreth J, Bakkenist CJ, McGee JO. (1999). Chromosomes, 11Q and cancer: a review. J Pathol 187: 28-38.
26. Kuang SQ, Liao L, Zhang H, Pereira FA, Yuan Y, DeMayo FJ et al. (2002). Deletion of the cancer-amplified coactivator AIB3 results in defective placentation and embryonic lethality. J Biol Chem 277: 45356-45360.
27. Lammie GA, Peters G. (1991). Chromosome 11q13 abnormalities in human cancer. Cancer Cells 3: 413-420.
28. Lee J, Rhee BK, Bae GY, Han YM, Kim J. (2005). Stimulation of Oct-4 activity by Ewing's sarcoma protein. Stem Cells 23: 738-751.
29. McKenna NJ, O'Malley BW. (2002). Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 108: 465-474.
30. Penalva LO, Sanchez L. (2003). RNA binding protein sex-lethal (Sxl) and control of Drosophila sex determination and dosage compensation. Microbiol Mol Biol Rev 67: 343-359, table of contents.
31. Rabbitts TH. (1994). Chromosomal translocations in human cancer. Nature 372: 143-149.
32. Rabbitts TH. (1999). Perspective: chromosomal translocations can affect genes controlling gene expression and differentiation - why are these functions targeted? J Pathol 187: 39-42.
33. Schmid CW. (1998). Does SINE evolution preclude Alu function? Nucleic Acids Res 26: 4541-4550.
34. Smith CW, Patton JG, Nadal-Ginard B. (1989). Alternative splicing in the control of gene expression. Annu Rev Genet 23: 527-577.
35. Sorensen PH, Triche TJ. (1996). Gene fusions encoding chimaeric transcription factors in solid tumours. Semin Cancer Biol 7: 3-14.
36. Torres-Arzayus MI, Font de Mora J, Yuan J, Vazquez F, Bronson R, Rue M et al. (2004). High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell 6: 263-274.
37. Yang L, Chansky HA, Hickstein DD. (2000). EWS.Fli-1 fusion protein interacts with hyperphosphorylated RNA polymerase II and interferes with serine-arginine protein-mediated RNA splicing. J Biol Chem 275: 37612-37618.
38. Yang XJ. (2004). The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases. Nucleic Acids Res 32: 959-976.
39. Zainabadi K, Benyamini P, Chakrabarti R, Veena MS, Chandrasekharappa SC, Gatti RA et al. (2005). A 700-kb physical and transcription map of the cervical cancer tumor suppressor gene locus on chromosome 11q13. Genomics 85: 704-714.
40. Zinszner H, Albalat R, Ron D. (1994). A novel effector domain from the RNA-binding protein TLS or EWS is required for oncogenic transformation by CHOP. Genes Dev 8: 2513-2526.